Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
-$0.04 today
- Market cap
- $212.10M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 1.22M
Average 1.19M
LCTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Lineage Cell Therapeutics, Inc.AMEX: LCTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $4.81M (cash outflow) rose 16.1% year over year, behind the +294.9% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +34.1% a year.
Context
- Net income amounted to 436.5% of revenue in FY2025, up 240.6 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$9.86M (-84.5%) for the fiscal year ending Dec 2026, a slowdown from the +241.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.81M-606.0% QoQ
- Last fiscal yearDec 2025
- -$63.53M+241.4% YoY
- LTMMar 2026
- -$64.01M+294.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +16.1% | -88.1% | -104.3 pp |
| 1 year | +241.4% | -84.5% | -325.9 pp |
| 3-year CAGR | +34.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (63.53M) USD
- Year-over-year change
- -241.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (63.53M) | -241.4% |
| FY2024 | 2024-12-31 | (18.61M) | +13.4% |
| FY2023 | 2023-12-31 | (21.49M) | +18.5% |
| FY2022 | 2022-12-31 | (26.35M) | +39.1% |
| FY2021 | 2021-12-31 | (43.27M) | — |
Net Income vs competitors
How LCTX compares with its peers on the latest reported figures
- LCTX's LTM Mar 2026 net income of $64.01M is the 3rd largest of the 4 companies compared; the peer median is $91.72M.
- Its year-over-year change of +294.9% is the 2nd highest of 4, against a peer median of +58.4%.
- Net income amounts to 433.1% of revenue for LCTX, versus a peer median of 176.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Dec 2025 | $91.72M | +58.4% | — | 345.4% | |
| LTM Mar 2026 | $64.01M | +294.9% | +34.1% | 433.1% | |
| LTM Jun 2026 | $8.67M | -91.5% | — | 7.2% | |
| Peer median (excluding LCTX) | $91.72M | +58.4% | -58.2% | 176.3% | |
Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.27M) | (26.35M) | (21.49M) | (18.61M) | (63.53M) |
| Depreciation & Amortization | 873K | 727K | 692K | 609K | 699K |
| Deferred Income Tax | (6M) | 0 | (1.8M) | 0 | (5.28M) |
| Stock-Based Compensation | 3.52M | 4.29M | 4.64M | 5.08M | 4.75M |
| Change in Working Capital | 21.11M | 18.67M | (10.8M) | (8.77M) | (4.11M) |
| Accounts Receivables | (857K) | 50.31M | (446K) | 106K | (316K) |
| Inventory | (72K) | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.65M | (18.7M) | (2.3M) | (1.68M) | 2.27M |
| Other Working Capital | 308K | (12.94M) | (8.06M) | (7.19M) | (6.07M) |
| Other Non-Cash Items | 202K | 3.73M | 195K | (1.4M) | 48.55M |
| Operating Cash Flow | (23.56M) | 1.06M | (28.57M) | (23.09M) | (18.92M) |
| Capital Expenditures | (354K) | (413K) | (674K) | (565K) | (522K) |
| Acquisitions (Net) | 10.09M | 45.75M | 0 | 0 | 0 |
| Purchases of Investments | 6.02M | (53.41M) | (16.4M) | (8.76M) | (14.94M) |
| Sales of Investments | (6.02M) | 7.67M | 63.53M | 7.02M | 2M |
| Other Investing Activities | 14K | (45.75M) | 0 | 0 | 0 |
| Investing Cash Flow | 9.75M | (46.16M) | 46.45M | (2.31M) | (13.46M) |
| Debt Repayment | (20K) | (32K) | (54K) | (54K) | (59K) |
| Common Stock Issued | 30.87M | 148K | 6.63M | 35.88M | 27.03M |
| Common Stock Repurchased | (54K) | (17K) | (37K) | (23K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.14M | 1.53M | (37K) | 58K | (16K) |
| Financing Cash Flow | 36.93M | 1.63M | 6.42M | 35.86M | 26.95M |
| Effect of Forex Changes | (20K) | (873K) | (250K) | (95K) | 396K |
| Net Change in Cash | 23.09M | (44.34M) | 24.06M | 10.36M | (5.03M) |
| Free Cash Flow | (23.92M) | 646K | (29.24M) | (23.66M) | (19.44M) |
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.